Galantamina: interakcje

Pyridostigmine bromide extended-release tablets are contraindicated in patients with: Mechanical intestinal or urinary obstruction Known hypersensitivity to pyridostigmine or other anticholinesterase agents Mechanical intestinal or urinary obstruction. (etykieta leku Pirydostygmina, Przeciwwskazania)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Dicyclomine hydrochloride should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (5.4) (etykieta leku Dicykloweryna, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. (etykieta leku Esmolol, Interakcje z innymi lekami)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

In case of simultaneous administration of other cholinesterase inhibitors (e.g. medicines for the treatment of dementia), caution should be exercised because of the potentiating effect. (etykieta leku Fizostygmina, Interakcje z innymi lekami)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Cholinesterase inhibitors: Concomitant administration may increase the risk of cocaine toxicity. (etykieta leku Kokaina, Interakcje z innymi lekami)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Use with caution due to aggravation of symptoms: Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), Parkinson’s disease ( 5.2 ), Myasthenia gravis ( 5.3 ), and Decreased gastrointestinal motility in patients with autonomic neuropathy ( 5.4 ). (etykieta leku Oksybutynina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Myasthenia Gravis Patients with myasthenia gravis may show worsening of symptoms from PA due to its procaine-like effect on diminishing acetylcholine release at skeletal muscle motor nerve endings, so that PA administration may be hazardous without optimal adjustment of anticholinesterase medications and other precautions. (etykieta leku Prokainamid, Ostrzeżenia)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Gastrointestinal Conditions Through their primary action, cholinomimetics may be expected to increase gastric acid secretion due to increased cholinergic activity. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

When Phase II block is suspected in cases of prolonged neuromuscular blockade, positive diagnosis should be made by peripheral nerve stimulation, prior to administration of any anticholinesterase drug. (etykieta leku Suksametonium, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etykieta leku Deksametazon, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. (etykieta leku Dipirydamol, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anticholinesterases : Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etykieta leku Metyloprednizolon, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anticholinesterase agents: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etykieta leku Prednizolon, Interakcje z innymi lekami)

Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etykieta leku Prednizon, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Synergistic effect expected when given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (etykieta leku Triamcynolon, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (etykieta leku Galantamina, Interakcje z innymi lekami)

Anesthesia Galantamine, as a cholinesterase inhibitor, is likely to exaggerate the neuromuscular blocking effects of succinylcholine-type and similar neuromuscular blocking agents during anesthesia. (etykieta leku Galantamina, Ostrzeżenia i środki ostrożności)

In drug interaction studies, oral RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6. (etykieta leku Rysperydon, Interakcje z innymi lekami)